OKYO Pharma Shifts ATM Facility to Leerink Partners for Flexible Capital Access
Event summary
- OKYO Pharma transitions its ATM equity offering facility from B. Riley Securities to Leerink Partners on February 11, 2026.
- Leerink Partners will act as the exclusive sales agent, receiving a 3.0% commission on gross proceeds from any shares sold.
- The move aims to enhance financial flexibility for ongoing clinical development, particularly for lead candidate urcosimod.
- OKYO Pharma plans to initiate a Phase 2b/3 study of urcosimod for neuropathic corneal pain in the first half of 2026.
The big picture
OKYO Pharma's shift to Leerink Partners for its ATM facility underscores a strategic focus on flexible capital access amid advancing clinical trials. The move aligns with broader trends in biotech financing, where companies seek to minimize market disruption while maintaining financial agility. The transition comes as OKYO Pharma prepares to initiate a pivotal Phase 2b/3 study for its lead candidate, urcosimod, highlighting the importance of stable funding for clinical development.
What we're watching
- Capital Efficiency
- How OKYO Pharma's ATM facility will impact its ability to raise capital without market disruption.
- Clinical Progress
- The pace at which OKYO Pharma advances its Phase 2b/3 study of urcosimod.
- Investor Relations
- Whether Leerink Partners' expertise will enhance OKYO Pharma's investor engagement and market positioning.